Innovative approaches for treating neurodegenerative diseases. Read More Our Projects See Projects

We promote, develop, and accelerate
high-impact scientific projects.

Mission

We are a company mainly dedicated to detecting and developing projects that could have an impact on neurodegenerative diseases. Specifically, we are interested in projects that study what we believe is their root cause, neuroinflammation. Our goal is to catalyze the transfer of these ideas from basic research laboratories to the pharmaceutical industry. We believe that our work will generate shortcuts towards early diagnosis strategies and novel therapeutic approaches for neurodegenerative diseases.

Vision

We believe in the potential of public-private ventures, where scientific knowledge from prestigious research organizations is complemented with funding, business capacity, and global connections that SkyBio can offer.

Our Projects

We are currently focusing on repurposing drugs capable of inhibiting aggregation, neuroinflammation, and mitochondrial damage.  Other vital and synergistic projects include discovering reliable ways to diagnose neurodegenerative diseases at early stages.

image-box
Novel Molecules

One of SkyBio’s main objectives is to design and test novel molecules based on our experience with structure-function relationships and structural predictions of existing commercial drugs and their interaction with neurotoxic protein.

image-box
Drug Repositioning

We study existing commercial drugs as potential neuroprotectants, to devise a multitask drug capable of inhibiting aggregation and neuroinflammation, while exhibiting good antioxidant activity in order to prevent mitochondrial damage.

image-box
Cutting Edge Research

So far there is no reliable biomarker for detecting or following the evolution of neurodegenerative diseases. We focus on developing new diagnostic methods for these pathologies.

Production Projects

2020 and the SARS-CoV-2 pandemic triggered added a new direction in projects that SkyBio has been developing, since 2017, with prestigious institutions under public-private Research and Development agreements. Always aligned with our Mission to detect and develop projects that have a high impact in medical sciences, and with the aim of catalyzing transfer to the pharmaceutical industry, SkyBio dedicated extensive resources to support Research and Development in the framework of the SARS-COV-2 pandemic, with significant achievements in 2 areas: therapy and detection.

image-box
Therapeutic Area: Production of monospecific polyclonal nanoantibodies
image-box
Detection Area: TEST ELISA-in house to quantify anti-RBD antibodies.
image-box
Other Projects: Production of recombinant proteins for diagnostic use